Physician
Neurosurgery
Dr. Thomas D. Meek, MD
|
|
Give Review
Thomas D. Meek practices Neurosurgery. He went to Baylor College of Medicine. Thomas Meek is also a published physician. He has 40 paper published. The most recent paper is: Inhibitor binding to the Phe53Trp mutant of HIV-1 protease promotes conformational changes detectable by spectrofluorometry.
Publications
- Transition state for the NSD2-catalyzed methylation of histone H3 lysine 36.
- Understanding the Origins of Time Dependent Inhibition by Polypeptide Deformylase Inhibitors.
- Kinetic mechanism and rate-limiting steps of focal adhesion kinase-1.
- Chemical mechanism of a cysteine protease, cathepsin C, as revealed by integration of both steady-state and pre-steady-state solvent kinetic isotope effects.
- Highly potent inhibitors of methionine aminopeptidase-2 based on a 1,2,4-triazole pharmacophore.
- Kinetic and chemical mechanisms of the fabG-encoded Streptococcus pneumoniae beta-ketoacyl-ACP reductase.
- 4-Aryl-1,2,3-triazole: a novel template for a reversible methionine aminopeptidase 2 inhibitor, optimized to inhibit angiogenesis in vivo.
- Kinetic mechanism of Escherichia coli glutamine synthetase.
- Purification and characterization of the bifunctional thymidylate synthetase-dihydrofolate reductase from methotrexate-resistant Leishmania tropica.
- Characterization and autoprocessing of precursor and mature forms of human immunodeficiency virus type 1 (HIV 1) protease purified from Escherichia coli.
- Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor.
- HIV-1 protease as a potential target for anti-AIDS therapy.
- Adaptation of the plasma renin radioimmunoassay for use with HIV-1 protease.
- Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells.
- Inhibitors of HIV-1 protease.
- A radiometric assay for HIV-1 protease.
- Peptide substrates and inhibitors of the HIV-1 protease.
- Escherichia coli glutamine synthetase. Determination of rate-limiting steps by rapid-quench and isotope partitioning experiments.
- Carbamoyl-phosphate synthetase II of the mammalian CAD protein: kinetic mechanism and elucidation of reaction intermediates by positional isotope exchange.
- Use of protein unfolding studies to determine the conformational and dimeric stabilities of HIV-1 and SIV proteases.
- Novel receptor antagonists welcome a new era in endothelin biology.
- Use of steady state kinetic methods to elucidate the kinetic and chemical mechanisms of retroviral proteases.
- Identification of a novel aspartic protease (Asp 2) as beta-secretase.
- ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site.
- Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease.
- Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues.
- Chromophoric peptide substrates for the spectrophotometric assay of HIV-1 protease.
- Inhibitor binding to the Phe53Trp mutant of HIV-1 protease promotes conformational changes detectable by spectrofluorometry.
- A symmetric inhibitor binds HIV-1 protease asymmetrically.
- cis-4-Carboxy-6-(mercaptomethyl)-3,4,5,6-tetrahydropyrimidin-2(1 H)-one , a potent inhibitor of mammalian dihydroorotase.
- Steady-state kinetic characterization of substrates and metal-ion specificities of the full-length and N-terminally truncated recombinant human methionine aminopeptida...
- Solvent isotope partitioning: a new kinetic tool for the determination of desorption rates of reactant water from enzyme-substrate complexes in proteases.
- Use of nitrogen-15 kinetic isotope effects to elucidate details of the chemical mechanism of human immunodeficiency virus 1 protease.
- Purification and biochemical characterization of recombinant simian immunodeficiency virus protease and comparison to human immunodeficiency virus type 1 protease.
- Mechanism of inhibition of cathepsin K by potent, selective 1, 5-diacylcarbohydrazides: a new class of mechanism-based inhibitors of thiol proteases.
- Rational design, synthesis, and crystallographic analysis of a hydroxyethylene-based HIV-1 protease inhibitor containing a heterocyclic P1'--P2' amide bond isostere.
- Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected ...
- Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism.
- Drug-target residence time and its implications for lead optimization.
Schools
Ohio State University College of Medicine
Riverside Methodist Hospital
Baylor University
Procedures Preformed
- Herniated Disc Surgery
Conditions Treated
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Degenerative Disc Disease
- Intervertebral Disc Herniation
- Low Back Pain
- View All
Doctors Specialties
- Neurosurgery
Accepted Insurances
- Blue Card PPO
- Blue Choice
- Commercial Insurance Company
- Medicare MCR
Education
-
Baylor College of Medicine -
Riverside Methodist Hospitals - OhioHealth -
The Ohio State University College of Medicine
Drug Facts
| NPI NUMBER | 1083713812 | |
| NPPES Provider LastName | MEEK | |
| NPPES Provider FirstName | THOMAS | |
| NPPES Provider ZIPCode | 286710000 | |
| NPPES Provider State | NC | |
| Specialty Description | Family Practice | |
| Total Claim Count | 417.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1083713812 |
| Last Name Of The Provider | MEEK |
| First Name Of The Provider | THOMAS |
| View All |
Similar Doctors
|
|
Dr. John K. Dorman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alim M. Ladha, MD
This Doctor is OpenDoctor Recommended.
|